Stem definition | Drug id | CAS RN |
---|---|---|
vasoconstrictors, vasopressin derivatives | 2810 | 113-79-1 |
Dose | Unit | Route |
---|---|---|
40 | U | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.10 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 5 % | Benet LZ, Broccatelli F, Oprea TI |
Date | Agency | Company | Orphan |
---|---|---|---|
None | FDA | PARKE DAVIS |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Cardiogenic shock | 168.61 | 37.67 | 57 | 3799 | 16268 | 56271943 |
Hypotension | 150.03 | 37.67 | 129 | 3727 | 250379 | 56037832 |
Shock | 134.61 | 37.67 | 52 | 3804 | 21676 | 56266535 |
Cardiac arrest | 132.41 | 37.67 | 79 | 3777 | 86235 | 56201976 |
Drug ineffective | 129.38 | 37.67 | 226 | 3630 | 918763 | 55369448 |
Septic shock | 110.00 | 37.67 | 62 | 3794 | 60773 | 56227438 |
Intentional overdose | 103.48 | 37.67 | 62 | 3794 | 68055 | 56220156 |
Metabolic acidosis | 94.81 | 37.67 | 49 | 3807 | 40405 | 56247806 |
Multiple organ dysfunction syndrome | 93.25 | 37.67 | 53 | 3803 | 52717 | 56235494 |
Vasoplegia syndrome | 88.05 | 37.67 | 20 | 3836 | 1305 | 56286906 |
Pulseless electrical activity | 86.37 | 37.67 | 28 | 3828 | 6996 | 56281215 |
Acute kidney injury | 78.21 | 37.67 | 89 | 3767 | 240674 | 56047537 |
Toxicity to various agents | 76.32 | 37.67 | 85 | 3771 | 224479 | 56063732 |
Lactic acidosis | 69.21 | 37.67 | 38 | 3818 | 35308 | 56252903 |
Circulatory collapse | 69.12 | 37.67 | 32 | 3824 | 20771 | 56267440 |
Local anaesthetic systemic toxicity | 59.29 | 37.67 | 13 | 3843 | 721 | 56287490 |
Peripheral ischaemia | 55.71 | 37.67 | 18 | 3838 | 4445 | 56283766 |
Disseminated intravascular coagulation | 48.69 | 37.67 | 24 | 3832 | 17861 | 56270350 |
Diabetes insipidus | 48.20 | 37.67 | 14 | 3842 | 2423 | 56285788 |
Hypothermia | 47.15 | 37.67 | 21 | 3835 | 12449 | 56275762 |
Respiratory failure | 44.85 | 37.67 | 43 | 3813 | 95019 | 56193192 |
Pulmonary oedema | 44.63 | 37.67 | 33 | 3823 | 51110 | 56237101 |
Acute respiratory distress syndrome | 38.61 | 37.67 | 22 | 3834 | 21904 | 56266307 |
Ventricular tachycardia | 38.19 | 37.67 | 20 | 3836 | 16881 | 56271330 |
Haemodynamic instability | 37.94 | 37.67 | 16 | 3840 | 8313 | 56279898 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Cardiogenic shock | 425.16 | 39.26 | 160 | 5915 | 22248 | 31669021 |
Appendicolith | 412.73 | 39.26 | 113 | 5962 | 5618 | 31685651 |
Multiple organ dysfunction syndrome | 364.32 | 39.26 | 201 | 5874 | 68002 | 31623267 |
Appendicitis | 335.45 | 39.26 | 113 | 5962 | 11352 | 31679917 |
Stress | 305.48 | 39.26 | 130 | 5945 | 24811 | 31666458 |
Ascites | 215.98 | 39.26 | 120 | 5955 | 40893 | 31650376 |
Drug ineffective | 198.39 | 39.26 | 304 | 5771 | 395269 | 31296000 |
Abdominal distension | 187.35 | 39.26 | 118 | 5957 | 50566 | 31640703 |
Sepsis | 175.22 | 39.26 | 178 | 5897 | 151751 | 31539518 |
Ventricular fibrillation | 171.91 | 39.26 | 80 | 5995 | 18768 | 31672501 |
Hyponatraemia | 158.16 | 39.26 | 123 | 5952 | 73676 | 31617593 |
General physical health deterioration | 128.83 | 39.26 | 132 | 5943 | 113303 | 31577966 |
Diabetes insipidus | 128.19 | 39.26 | 38 | 6037 | 2502 | 31688767 |
Vasoplegia syndrome | 96.88 | 39.26 | 28 | 6047 | 1685 | 31689584 |
Abdominal pain | 90.89 | 39.26 | 125 | 5950 | 145827 | 31545442 |
Constipation | 89.20 | 39.26 | 114 | 5961 | 123877 | 31567392 |
Blood phosphorus increased | 88.34 | 39.26 | 33 | 6042 | 4449 | 31686820 |
Shock | 71.86 | 39.26 | 48 | 6027 | 22597 | 31668672 |
Hypotension | 69.38 | 39.26 | 133 | 5942 | 204485 | 31486784 |
Off label use | 58.79 | 39.26 | 172 | 5903 | 347102 | 31344167 |
Vomiting | 54.27 | 39.26 | 127 | 5948 | 223846 | 31467423 |
Renal injury | 52.70 | 39.26 | 30 | 6045 | 10635 | 31680634 |
Lactic acidosis | 49.03 | 39.26 | 44 | 6031 | 31893 | 31659376 |
Cardiac arrest | 48.96 | 39.26 | 72 | 6003 | 88990 | 31602279 |
Diarrhoea | 44.98 | 39.26 | 7 | 6068 | 352402 | 31338867 |
Fatigue | 44.30 | 39.26 | 6 | 6069 | 335200 | 31356069 |
Serotonin syndrome | 43.80 | 39.26 | 33 | 6042 | 18740 | 31672529 |
Pulse absent | 43.37 | 39.26 | 21 | 6054 | 5356 | 31685913 |
Septic shock | 41.52 | 39.26 | 57 | 6018 | 66101 | 31625168 |
Metabolic acidosis | 41.05 | 39.26 | 44 | 6031 | 39533 | 31651736 |
Respiratory failure | 40.62 | 39.26 | 71 | 6004 | 101378 | 31589891 |
Compartment syndrome | 39.61 | 39.26 | 16 | 6059 | 2655 | 31688614 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Cardiogenic shock | 581.64 | 29.03 | 211 | 9756 | 36096 | 70882381 |
Appendicolith | 443.14 | 29.03 | 112 | 9855 | 5568 | 70912909 |
Multiple organ dysfunction syndrome | 436.50 | 29.03 | 239 | 9728 | 108276 | 70810201 |
Appendicitis | 323.67 | 29.03 | 112 | 9855 | 16621 | 70901856 |
Drug ineffective | 304.72 | 29.03 | 500 | 9467 | 939252 | 69979225 |
Stress | 222.33 | 29.03 | 131 | 9836 | 67835 | 70850642 |
Ascites | 207.40 | 29.03 | 125 | 9842 | 67422 | 70851055 |
Sepsis | 206.05 | 29.03 | 210 | 9757 | 244335 | 70674142 |
Ventricular fibrillation | 195.62 | 29.03 | 89 | 9878 | 27022 | 70891455 |
Vasoplegia syndrome | 191.56 | 29.03 | 51 | 9916 | 3105 | 70915372 |
Shock | 181.51 | 29.03 | 96 | 9871 | 40329 | 70878148 |
Hypotension | 176.10 | 29.03 | 248 | 9719 | 404133 | 70514344 |
Diabetes insipidus | 171.78 | 29.03 | 51 | 9916 | 4620 | 70913857 |
Abdominal distension | 145.05 | 29.03 | 119 | 9848 | 104550 | 70813927 |
Cardiac arrest | 143.04 | 29.03 | 142 | 9825 | 159692 | 70758785 |
Hyponatraemia | 128.25 | 29.03 | 134 | 9833 | 159953 | 70758524 |
Metabolic acidosis | 123.31 | 29.03 | 94 | 9873 | 74252 | 70844225 |
Septic shock | 114.04 | 29.03 | 107 | 9860 | 112151 | 70806326 |
Lactic acidosis | 107.34 | 29.03 | 82 | 9885 | 64942 | 70853535 |
Intentional overdose | 92.68 | 29.03 | 90 | 9877 | 98345 | 70820132 |
General physical health deterioration | 92.47 | 29.03 | 138 | 9829 | 235893 | 70682584 |
Acute kidney injury | 86.13 | 29.03 | 199 | 9768 | 474425 | 70444052 |
Blood phosphorus increased | 85.03 | 29.03 | 33 | 9934 | 6737 | 70911740 |
Pulseless electrical activity | 81.67 | 29.03 | 39 | 9928 | 13176 | 70905301 |
Respiratory failure | 79.82 | 29.03 | 108 | 9859 | 168627 | 70749850 |
Fatigue | 77.17 | 29.03 | 12 | 9955 | 824307 | 70094170 |
Toxicity to various agents | 65.67 | 29.03 | 157 | 9810 | 382015 | 70536462 |
Haemodynamic instability | 64.09 | 29.03 | 35 | 9932 | 15623 | 70902854 |
Peripheral ischaemia | 60.76 | 29.03 | 28 | 9939 | 8730 | 70909747 |
Acute respiratory distress syndrome | 59.35 | 29.03 | 48 | 9919 | 41206 | 70877271 |
Headache | 57.65 | 29.03 | 7 | 9960 | 580398 | 70338079 |
Overdose | 57.64 | 29.03 | 93 | 9874 | 169652 | 70748825 |
Off label use | 56.85 | 29.03 | 230 | 9737 | 742830 | 70175647 |
Renal injury | 55.10 | 29.03 | 32 | 9935 | 16062 | 70902415 |
Abdominal pain | 54.94 | 29.03 | 137 | 9830 | 341990 | 70576487 |
Constipation | 54.87 | 29.03 | 114 | 9853 | 252324 | 70666153 |
Circulatory collapse | 54.71 | 29.03 | 43 | 9924 | 35431 | 70883046 |
Serotonin syndrome | 54.33 | 29.03 | 46 | 9921 | 42068 | 70876409 |
Arthralgia | 52.71 | 29.03 | 5 | 9962 | 503385 | 70415092 |
Dizziness | 50.25 | 29.03 | 4 | 9963 | 464137 | 70454340 |
Pulse absent | 50.04 | 29.03 | 25 | 9942 | 9305 | 70909172 |
Drug ineffective for unapproved indication | 49.52 | 29.03 | 42 | 9925 | 38496 | 70879981 |
Local anaesthetic systemic toxicity | 47.87 | 29.03 | 13 | 9954 | 852 | 70917625 |
Hyperdynamic left ventricle | 47.87 | 29.03 | 11 | 9956 | 362 | 70918115 |
Distributive shock | 43.31 | 29.03 | 15 | 9952 | 2222 | 70916255 |
Compartment syndrome | 42.98 | 29.03 | 18 | 9949 | 4468 | 70914009 |
Rash | 42.23 | 29.03 | 10 | 9957 | 510552 | 70407925 |
Bradycardia | 40.54 | 29.03 | 67 | 9900 | 124548 | 70793929 |
Electrocardiogram QRS complex prolonged | 40.35 | 29.03 | 22 | 9945 | 9784 | 70908693 |
Diarrhoea | 40.11 | 29.03 | 31 | 9936 | 783310 | 70135167 |
Heparin-induced thrombocytopenia | 39.21 | 29.03 | 21 | 9946 | 9016 | 70909461 |
Acidosis | 39.14 | 29.03 | 27 | 9940 | 18236 | 70900241 |
Malaise | 38.85 | 29.03 | 7 | 9960 | 432925 | 70485552 |
Dyspnoea | 38.76 | 29.03 | 31 | 9936 | 770029 | 70148448 |
Renal failure | 38.28 | 29.03 | 83 | 9884 | 188987 | 70729490 |
Disseminated intravascular coagulation | 37.89 | 29.03 | 34 | 9933 | 33564 | 70884913 |
Dry gangrene | 33.96 | 29.03 | 10 | 9957 | 879 | 70917598 |
Acute respiratory failure | 32.68 | 29.03 | 39 | 9928 | 53626 | 70864851 |
Ventricular tachycardia | 31.81 | 29.03 | 32 | 9935 | 36391 | 70882086 |
Fear | 31.59 | 29.03 | 25 | 9942 | 20786 | 70897691 |
Renal tubular necrosis | 31.30 | 29.03 | 26 | 9941 | 23145 | 70895332 |
Intestinal ischaemia | 31.07 | 29.03 | 20 | 9947 | 12044 | 70906433 |
Ischaemic hepatitis | 30.70 | 29.03 | 13 | 9954 | 3316 | 70915161 |
Anhedonia | 30.42 | 29.03 | 21 | 9946 | 14192 | 70904285 |
Coma scale abnormal | 30.08 | 29.03 | 17 | 9950 | 8099 | 70910378 |
Hypernatraemia | 30.04 | 29.03 | 20 | 9947 | 12741 | 70905736 |
Asthenia | 29.09 | 29.03 | 14 | 9953 | 457652 | 70460825 |
None
Source | Code | Description |
---|---|---|
ATC | H01BA01 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES POSTERIOR PITUITARY LOBE HORMONES Vasopressin and analogues |
FDA CS | M0022562 | Vasopressins |
FDA PE | N0000009908 | Vasoconstriction |
FDA PE | N0000175360 | Decreased Diuresis |
MeSH PA | D050034 | Antidiuretic Agents |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D003029 | Coagulants |
MeSH PA | D006401 | Hematologic Agents |
MeSH PA | D006490 | Hemostatics |
MeSH PA | D045283 | Natriuretic Agents |
MeSH PA | D014662 | Vasoconstrictor Agents |
CHEBI has role | CHEBI:35554 | cardiovascular agent |
CHEBI has role | CHEBI:50248 | hematologic agents |
CHEBI has role | CHEBI:52290 | mitogens |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Nocturnal enuresis | indication | 8009008 | |
Hereditary factor VIII deficiency disease | indication | 28293008 | DOID:12134 |
von Willebrand disorder | indication | 128105004 | DOID:12531 |
Partial Central Diabetes Insipidus | indication | ||
Cardiac arrest | off-label use | 410429000 | DOID:0060319 |
Uremic Bleeding Tendency | off-label use | ||
Chronic glomerulonephritis | contraindication | 20917003 | |
Migraine | contraindication | 37796009 | DOID:6364 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Uremia | contraindication | 44730006 | DOID:4676 |
Heart failure | contraindication | 84114007 | DOID:6000 |
Epilepsy | contraindication | 84757009 | DOID:1826 |
Asthma | contraindication | 195967001 | DOID:2841 |
Disorder of coronary artery | contraindication | 414024009 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.65 | acidic |
pKa2 | 12.19 | acidic |
pKa3 | 12.56 | acidic |
pKa4 | 12.85 | acidic |
pKa5 | 13.19 | acidic |
pKa6 | 13.43 | acidic |
pKa7 | 13.76 | acidic |
pKa8 | 10.75 | Basic |
pKa9 | 6.4 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
200UNITS/10ML (20UNITS/ML) | VASOSTRICT | PAR STERILE PRODUCTS | N204485 | Dec. 17, 2016 | RX | SOLUTION | INTRAVENOUS | 9375478 | Jan. 30, 2035 | TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES |
200UNITS/10ML (20UNITS/ML) | VASOSTRICT | PAR STERILE PRODUCTS | N204485 | Dec. 17, 2016 | RX | SOLUTION | INTRAVENOUS | 9687526 | Jan. 30, 2035 | TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES |
200UNITS/10ML (20UNITS/ML) | VASOSTRICT | PAR STERILE PRODUCTS | N204485 | Dec. 17, 2016 | RX | SOLUTION | INTRAVENOUS | 9744209 | Jan. 30, 2035 | TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES |
200UNITS/10ML (20UNITS/ML) | VASOSTRICT | PAR STERILE PRODUCTS | N204485 | Dec. 17, 2016 | RX | SOLUTION | INTRAVENOUS | 9744239 | Jan. 30, 2035 | TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES |
200UNITS/10ML (20UNITS/ML) | VASOSTRICT | PAR STERILE PRODUCTS | N204485 | Dec. 17, 2016 | RX | SOLUTION | INTRAVENOUS | 9937223 | Jan. 30, 2035 | TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES |
20UNITS/100ML (0.2UNITS/ML) | VASOSTRICT | PAR STERILE PRODUCTS | N204485 | April 21, 2021 | RX | SOLUTION | INTRAVENOUS | 10010575 | Jan. 30, 2035 | TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES |
20UNITS/100ML (0.2UNITS/ML) | VASOSTRICT | PAR STERILE PRODUCTS | N204485 | April 21, 2021 | RX | SOLUTION | INTRAVENOUS | 9925233 | Jan. 30, 2035 | TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES |
20UNITS/100ML (0.2UNITS/ML) | VASOSTRICT | PAR STERILE PRODUCTS | N204485 | April 21, 2021 | RX | SOLUTION | INTRAVENOUS | 9925234 | Jan. 30, 2035 | TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES |
20UNITS/100ML (0.2UNITS/ML) | VASOSTRICT | PAR STERILE PRODUCTS | N204485 | April 21, 2021 | RX | SOLUTION | INTRAVENOUS | 9962422 | Jan. 30, 2035 | TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES |
20UNITS/100ML (0.2UNITS/ML) | VASOSTRICT | PAR STERILE PRODUCTS | N204485 | April 21, 2021 | RX | SOLUTION | INTRAVENOUS | 9968649 | Jan. 30, 2035 | TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES |
20UNITS/100ML (0.2UNITS/ML) | VASOSTRICT | PAR STERILE PRODUCTS | N204485 | April 21, 2021 | RX | SOLUTION | INTRAVENOUS | 9974827 | Jan. 30, 2035 | TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES |
20UNITS/100ML (0.2UNITS/ML) | VASOSTRICT | PAR STERILE PRODUCTS | N204485 | April 21, 2021 | RX | SOLUTION | INTRAVENOUS | 9981006 | Jan. 30, 2035 | TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES |
20UNITS/ML (20UNITS/ML) | VASOSTRICT | PAR STERILE PRODUCTS | N204485 | April 17, 2014 | RX | SOLUTION | INTRAVENOUS | 9375478 | Jan. 30, 2035 | TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES |
20UNITS/ML (20UNITS/ML) | VASOSTRICT | PAR STERILE PRODUCTS | N204485 | April 17, 2014 | RX | SOLUTION | INTRAVENOUS | 9687526 | Jan. 30, 2035 | TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES |
20UNITS/ML (20UNITS/ML) | VASOSTRICT | PAR STERILE PRODUCTS | N204485 | April 17, 2014 | RX | SOLUTION | INTRAVENOUS | 9744209 | Jan. 30, 2035 | TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES |
20UNITS/ML (20UNITS/ML) | VASOSTRICT | PAR STERILE PRODUCTS | N204485 | April 17, 2014 | RX | SOLUTION | INTRAVENOUS | 9744239 | Jan. 30, 2035 | TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES |
40UNITS/100ML (0.4UNITS/ML) | VASOSTRICT | PAR STERILE PRODUCTS | N204485 | April 15, 2020 | RX | SOLUTION | INTRAVENOUS | 10010575 | Jan. 30, 2035 | TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES |
40UNITS/100ML (0.4UNITS/ML) | VASOSTRICT | PAR STERILE PRODUCTS | N204485 | April 15, 2020 | RX | SOLUTION | INTRAVENOUS | 9925233 | Jan. 30, 2035 | TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES |
40UNITS/100ML (0.4UNITS/ML) | VASOSTRICT | PAR STERILE PRODUCTS | N204485 | April 15, 2020 | RX | SOLUTION | INTRAVENOUS | 9925234 | Jan. 30, 2035 | TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES |
40UNITS/100ML (0.4UNITS/ML) | VASOSTRICT | PAR STERILE PRODUCTS | N204485 | April 15, 2020 | RX | SOLUTION | INTRAVENOUS | 9962422 | Jan. 30, 2035 | TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES |
40UNITS/100ML (0.4UNITS/ML) | VASOSTRICT | PAR STERILE PRODUCTS | N204485 | April 15, 2020 | RX | SOLUTION | INTRAVENOUS | 9968649 | Jan. 30, 2035 | TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES |
40UNITS/100ML (0.4UNITS/ML) | VASOSTRICT | PAR STERILE PRODUCTS | N204485 | April 15, 2020 | RX | SOLUTION | INTRAVENOUS | 9974827 | Jan. 30, 2035 | TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES |
40UNITS/100ML (0.4UNITS/ML) | VASOSTRICT | PAR STERILE PRODUCTS | N204485 | April 15, 2020 | RX | SOLUTION | INTRAVENOUS | 9981006 | Jan. 30, 2035 | TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES |
60UNITS/100ML (0.6UNITS/ML) | VASOSTRICT | PAR STERILE PRODUCTS | N204485 | April 15, 2020 | RX | SOLUTION | INTRAVENOUS | 10010575 | Jan. 30, 2035 | TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES |
60UNITS/100ML (0.6UNITS/ML) | VASOSTRICT | PAR STERILE PRODUCTS | N204485 | April 15, 2020 | RX | SOLUTION | INTRAVENOUS | 9925233 | Jan. 30, 2035 | TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES |
60UNITS/100ML (0.6UNITS/ML) | VASOSTRICT | PAR STERILE PRODUCTS | N204485 | April 15, 2020 | RX | SOLUTION | INTRAVENOUS | 9925234 | Jan. 30, 2035 | TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES |
60UNITS/100ML (0.6UNITS/ML) | VASOSTRICT | PAR STERILE PRODUCTS | N204485 | April 15, 2020 | RX | SOLUTION | INTRAVENOUS | 9962422 | Jan. 30, 2035 | TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES |
60UNITS/100ML (0.6UNITS/ML) | VASOSTRICT | PAR STERILE PRODUCTS | N204485 | April 15, 2020 | RX | SOLUTION | INTRAVENOUS | 9968649 | Jan. 30, 2035 | TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES |
60UNITS/100ML (0.6UNITS/ML) | VASOSTRICT | PAR STERILE PRODUCTS | N204485 | April 15, 2020 | RX | SOLUTION | INTRAVENOUS | 9974827 | Jan. 30, 2035 | TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES |
60UNITS/100ML (0.6UNITS/ML) | VASOSTRICT | PAR STERILE PRODUCTS | N204485 | April 15, 2020 | RX | SOLUTION | INTRAVENOUS | 9981006 | Jan. 30, 2035 | TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
20UNITS/ML (20UNITS/ML) | VASOPRESSIN | EAGLE PHARMS | A211538 | Dec. 15, 2021 | RX | SOLUTION | INTRAVENOUS | July 17, 2022 | PATENT CHALLENGE |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Vasopressin V1a receptor | GPCR | AGONIST | Ki | 9.59 | CHEMBL | CHEMBL | |||
Vasopressin V1b receptor | GPCR | AGONIST | Ki | 9.31 | CHEMBL | CHEMBL | |||
Vasopressin V2 receptor | GPCR | AGONIST | Ki | 8.92 | CHEMBL | CHEMBL | |||
Oxytocin receptor | GPCR | Ki | 8.78 | CHEMBL | |||||
Vasopressin V2 receptor | GPCR | IC50 | 8.48 | CHEMBL | |||||
Oxytocin receptor | GPCR | Ki | 8.93 | CHEMBL | |||||
Vasopressin V2 receptor | GPCR | Ki | 9.35 | CHEMBL | |||||
Vasopressin V2 receptor | GPCR | Kd | 8.82 | CHEMBL | |||||
Vasopressin V1a receptor | GPCR | Kd | 9.19 | CHEMBL | |||||
Vasopressin V1b receptor | GPCR | Ki | 9.54 | CHEMBL | |||||
Vasopressin V1 receptor | GPCR | Kd | 9.19 | CHEMBL |
ID | Source |
---|---|
4018654 | VUID |
N0000179795 | NUI |
D00101 | KEGG_DRUG |
4018654 | VANDF |
C1705480 | UMLSCUI |
CHEBI:9937 | CHEBI |
CHEMBL373742 | ChEMBL_ID |
CHEMBL2108986 | ChEMBL_ID |
DB00067 | DRUGBANK_ID |
2168 | IUPHAR_LIGAND_ID |
C016671 | MESH_SUPPLEMENTAL_RECORD_UI |
Y4907O6MFD | UNII |
1098 | RXNORM |
3144 | MMSL |
5667 | MMSL |
d00398 | MMSL |
002122 | NDDF |
002123 | NDDF |
002126 | NDDF |
005438 | NDDF |
005439 | NDDF |
126192003 | SNOMEDCT_US |
421078009 | SNOMEDCT_US |
772208008 | SNOMEDCT_US |
77671006 | SNOMEDCT_US |
CHEMBL1201528 | ChEMBL_ID |
644077 | PUBCHEM_CID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Vasopressin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0517-1020 | INJECTION, SOLUTION | 20 [USPU] | INTRAVENOUS | NDA | 25 sections |
Vasopressin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0517-1020 | INJECTION, SOLUTION | 20 [USPU] | INTRAVENOUS | NDA | 25 sections |
Vasopressin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0548-9701 | INJECTION | 20 [USPU] | INTRAVENOUS | ANDA | 24 sections |
VASOPRESSIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42367-570 | INJECTION | 20 U | PARENTERAL | ANDA | 24 sections |
vasopressin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70121-1642 | INJECTION | 20 [USPU] | INTRAVENOUS | ANDA | 20 sections |